Raw Deflazacort Powder (14484-47-0) hplc≥98% | AASraw
AASraw produces Cannabidiol(CBD) powder and Hemp Essential Oil in bulk!

Deflazacort Powder (14484-47-0)

Rating: SKU: 14484-47-0. Category:

AASraw is with synthesis and production ability from gram to mass order of Deflazacort Powder (14484-47-0), under CGMP regulation and trackable quality control system.

AASRAW powder PDF Icon

Product Description


Deflazacort Powder (14484-47-0) video




Deflazacort Powder (14484-47-0) Specification:

Chemical Structure: Product Name: Deflazacort
Cas No.: 14484-47-0
Molecular Formula: C25H31NO6
Molecular Weight: 441.51674
Standard: In-house
Storage: Dry, dark and at 0 – 4 C for short term (days to weeks) or -20 C for long term (months to years).
Documents(COA & HPLC etc.): Available

Deflazacort Powder (14484-47-0) Description:

Deflazacort (trade name Emflaza among others) is a glucocorticoid used as an anti-inflammatory and immunosuppressant. Deflazacort is a prodrug. Its potency is around 70–90% that of prednisone.It belongs to a group of medicines called corticosteroids. It is sometimes referred to simply as an oral steroid. Deflazacort is an inactive prodrug which is metabolized rapidly to the active drug 21-desacetyldeflazacort.It is used to treat a wide variety of conditions. Some examples include autoimmune diseases (for example, systemic lupus erythematosus (SLE), autoimmune hepatitis, sarcoidosis), joint and muscle diseases (for example, rheumatoid arthritis), and allergies and asthma.



  • 1: McDonald CM, Sajeev G, Yao Z, McDonnell E, Elfring G, Souza M, Peltz SW, Darras BT, Shieh PB, Cox DA, Landry J, Signorovitch J; ACT DMD Study Group and the Tadalafil DMD Study Group. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent multicenter clinical trials. Muscle Nerve. 2019 Oct 10. doi: 10.1002/mus.26736. [Epub ahead of print] PubMed PMID: 31599456.
  • 2: Kucukpolat S, Kocaaslan R, Kadihasanoglu M, Bagcioglu M, Kocan H, Sarica K. Is Medical Therapy for Distal Ureteral Stones Efficient? Tamsulosin versus Deflazacort: A Prospective Randomised Trial. Aktuelle Urol. 2019 Sep 19. doi: 10.1055/a-0770-2627. [Epub ahead of print] PubMed PMID: 31537025.
  • 3: Tantawy MA, Alweshahy S, Elshabasy DA, Youssef NF. Simultaneous Determination of Co-administrated Deflazacort, Aprepitant and Granisetron in Dosage Forms and Spiked Human Plasma by RP-HPLC/PAD. J Chromatogr Sci. 2019 Aug 28. pii: bmz062. doi: 10.1093/chromsci/bmz062. [Epub ahead of print] PubMed PMID: 31504281.